Anne M. Dickinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne M. Dickinson has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
E. Holler
Universitätsklinikum Hämatologie/Onkologie, Regensburg, Germany
2 shared publicationsGraham Jackson
2 shared publicationsHannah Cullup
School of Clinical and Laboratory Sciences, Institute of Cellular Medicine, Newcastle University Medical School, Newcastle upon Tyne, UK
2 shared publications- Ilona Hromadnikova
Department of Molecular Biology and Cell Pathology, Third faculty of Medicine Charles University Prague Czech Republic
2 shared publications - Nicholas J. Morris
School of Biomedical Sciences, Newcastle University, Newcastle Upon Tyne NE2 4HH, UK
2 shared publications P. Sedlacek
2nd Medical Faculty, Charles University, Prague, Czech Republic
2 shared publications
Latest Publications
- 16 May 2011
- Published by Wolters Kluwer Health in Transplantation
- Vol. 91 (9) , 946-951
The Involvement of Epithelial Fas in a Human Model of Graft Versus Host Disease
Background. Graft-versus-host disease (GVHD) is an important complication occurring after hematopoietic stem-cell transplantation (HSCT). Animal model studies have shown the involvement of the Fas (APO-1/CD95)/Fas-Ligand pathway in GVHD pathogenesis, but its association with cutaneous GVHD in human remains to be established. Methods. In the present study, Fas involvement in skin damage was assessed using a human skin explant model of GVHD. Fas and FasL expression were measured by immunohistochemistry and blockade of Fas pathway was investigated using an antagonistic anti-human Fas monoclonal antibody. In addition, levels of soluble Fas (sFas) were determined in the serum of patients receiving allogeneic HSCT with and without GVHD. Results. The results showed that Fas up-regulation in the epithelium of human skin explants correlated with graft-versus-host reaction (GVHR) in the skin explant model (PP<0.001) but rather than being associated with the severity of GVHD, sFas levels differed with the conditioning treatments the patients received before the HSCT. Conclusions. Higher GVHR grades were associated with increased Fas expression in the epithelium of the skin explants. In addition, by blocking Fas-mediated apoptosis, the GVHR grades were decreased. Our study thus shows the involvement of Fas in cutaneous GVHD damage, and supports the potential use of Fas as a therapeutic target.
- 16 May 2011
- Published by Wolters Kluwer Health in Transplantation
- Vol. 91 (9) , 946-951
The Involvement of Epithelial Fas in a Human Model of Graft Versus Host Disease
Background. Graft-versus-host disease (GVHD) is an important complication occurring after hematopoietic stem-cell transplantation (HSCT). Animal model studies have shown the involvement of the Fas (APO-1/CD95)/Fas-Ligand pathway in GVHD pathogenesis, but its association with cutaneous GVHD in human remains to be established. Methods. In the present study, Fas involvement in skin damage was assessed using a human skin explant model of GVHD. Fas and FasL expression were measured by immunohistochemistry and blockade of Fas pathway was investigated using an antagonistic anti-human Fas monoclonal antibody. In addition, levels of soluble Fas (sFas) were determined in the serum of patients receiving allogeneic HSCT with and without GVHD. Results. The results showed that Fas up-regulation in the epithelium of human skin explants correlated with graft-versus-host reaction (GVHR) in the skin explant model (PP<0.001) but rather than being associated with the severity of GVHD, sFas levels differed with the conditioning treatments the patients received before the HSCT. Conclusions. Higher GVHR grades were associated with increased Fas expression in the epithelium of the skin explants. In addition, by blocking Fas-mediated apoptosis, the GVHR grades were decreased. Our study thus shows the involvement of Fas in cutaneous GVHD damage, and supports the potential use of Fas as a therapeutic target.
- 15 April 2011
- Published by Wolters Kluwer Health in Transplantation
- Vol. 91 (7) , 731-736
Prognostic Significance of Interleukin-7 Receptor-α Gene Polymorphisms in Allogeneic Stem-Cell Transplantation: A Confirmatory Study
Interleukin-7 (IL-7) is a hematopoietic cytokine essential for T-cell development in the thymus and for the maintenance of peripheral T cells. A previous study of single nucleotide polymorphisms in the exons of IL-7 receptor α-chain (IL-7Rα) in a Danish cohort of patients undergoing allogeneic stem-cell transplantation (SCT) identified donor genotype GG at rs1494555 as a risk factor for treatment-related mortality (TRM) after SCT. In this validation study, 116 British and French SCT patients and their donors were investigated by sequence-specific primer polymerase chain reaction. Both donor rs1494555GG genotype and the tightly coupled rs1494558TT genotype were significantly associated with grade 3 to 4 acute graft versus host disease. Although both genotypes tended to be associated with increased TRM, this did not translate into altered overall survival. The present data indicate that the IL-7 pathway is associated with alloreactivity in SCT, which is in line with the previously observed association between IL-7Rα single nucleotide polymorphisms and TRM.
- 15 April 2011
- Published by Wolters Kluwer Health in Transplantation
- Vol. 91 (7) , 731-736
Prognostic Significance of Interleukin-7 Receptor-α Gene Polymorphisms in Allogeneic Stem-Cell Transplantation: A Confirmatory Study
Interleukin-7 (IL-7) is a hematopoietic cytokine essential for T-cell development in the thymus and for the maintenance of peripheral T cells. A previous study of single nucleotide polymorphisms in the exons of IL-7 receptor α-chain (IL-7Rα) in a Danish cohort of patients undergoing allogeneic stem-cell transplantation (SCT) identified donor genotype GG at rs1494555 as a risk factor for treatment-related mortality (TRM) after SCT. In this validation study, 116 British and French SCT patients and their donors were investigated by sequence-specific primer polymerase chain reaction. Both donor rs1494555GG genotype and the tightly coupled rs1494558TT genotype were significantly associated with grade 3 to 4 acute graft versus host disease. Although both genotypes tended to be associated with increased TRM, this did not translate into altered overall survival. The present data indicate that the IL-7 pathway is associated with alloreactivity in SCT, which is in line with the previously observed association between IL-7Rα single nucleotide polymorphisms and TRM.
- Open Access
- 1 April 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (14) , 12803-12811
HSP70 Natively and Specifically Associates with an N-terminal Dermcidin-derived Peptide That Contains an HLA-A*03 Antigenic Epitope
- 1 April 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (14) , 12803-12811
Open AccessHSP70 Natively and Specifically Associates with an N-terminal Dermcidin-derived Peptide That Contains an HLA-A*03 Antigenic Epitope
- Open Access
- 1 September 2010
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 15 (5) , 729-741
Identification of potential HLA class I and class II epitope precursors associated with heat shock protein 70 (HSPA)
- 1 September 2010
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 15 (5) , 729-741
Open AccessIdentification of potential HLA class I and class II epitope precursors associated with heat shock protein 70 (HSPA)
- Open Access
- 19 March 2010
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (6) , 922-927
Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia
Background Non-HLA gene polymorphisms have been shown to influence outcome after allogeneic hematopoietic stem cell transplantation. Results were derived from heterogeneous, small populations and their value remains a matter of debate. Design and Methods In this study, we assessed the effect of single nucleotide polymorphisms in genes for interleukin 1 receptor antagonist (IL1RN), interleukin 4 (IL4), interleukin 6 (IL6), interleukin 10 (IL10), interferon (IFNG), tumor necrosis factor (TNF) and the cell surface receptors tumor necrosis factor receptor II (TNFRSFIB), vitamin D receptor (VDR) and estrogen receptor alpha (ESR1) in a homogeneous cohort of 228 HLA identical sibling transplants for chronic myeloid leukemia. Three good predictors of overall survival, identified via statistical methods including Cox regression analysis, were investigated for their effects on transplant-related mortality and relapse. Predictive power was assessed after integration into the established European Group for Blood and Marrow Transplantation (EBMT) risk score. Results Absence of patient TNFRSFIB 196R, absence of donor IL10 ATA/ACC and presence of donor IL1RN allele 2 genotypes were associated with increased transplantation-related mortality and decreased survival. Application of prediction error and concordance index statistics gave evidence that integration improved the EBMT risk score. Conclusions Non-HLA genotypes were associated with survival after allogeneic hematopoietic stem cell transplantation. When three genetic polymorphisms were added into the EBMT risk model they improved the goodness of fit. Non-HLA genotyping could, therefore, be used to improve donor selection algorithms and risk assessment prior to allogeneic hematopoietic stem cell transplantation.
- 19 March 2010
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (6) , 922-927
Open AccessImpact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia
Background Non-HLA gene polymorphisms have been shown to influence outcome after allogeneic hematopoietic stem cell transplantation. Results were derived from heterogeneous, small populations and their value remains a matter of debate. Design and Methods In this study, we assessed the effect of single nucleotide polymorphisms in genes for interleukin 1 receptor antagonist (IL1RN), interleukin 4 (IL4), interleukin 6 (IL6), interleukin 10 (IL10), interferon (IFNG), tumor necrosis factor (TNF) and the cell surface receptors tumor necrosis factor receptor II (TNFRSFIB), vitamin D receptor (VDR) and estrogen receptor alpha (ESR1) in a homogeneous cohort of 228 HLA identical sibling transplants for chronic myeloid leukemia. Three good predictors of overall survival, identified via statistical methods including Cox regression analysis, were investigated for their effects on transplant-related mortality and relapse. Predictive power was assessed after integration into the established European Group for Blood and Marrow Transplantation (EBMT) risk score. Results Absence of patient TNFRSFIB 196R, absence of donor IL10 ATA/ACC and presence of donor IL1RN allele 2 genotypes were associated with increased transplantation-related mortality and decreased survival. Application of prediction error and concordance index statistics gave evidence that integration improved the EBMT risk score. Conclusions Non-HLA genotypes were associated with survival after allogeneic hematopoietic stem cell transplantation. When three genetic polymorphisms were added into the EBMT risk model they improved the goodness of fit. Non-HLA genotyping could, therefore, be used to improve donor selection algorithms and risk assessment prior to allogeneic hematopoietic stem cell transplantation.
- 1 August 2008
- Published by Wiley in International Journal of Immunogenetics
- Vol. 35 (4-5) , 375-380
Non‐HLA genetics and predicting outcome in HSCT
Summary: Over the last 10 years, an increasing number of studies have demonstrated the role of non‐human leukocyte antigen (HLA) genes in predicting outcome in haematopoietic stem cell transplantation (HSCT). These studies have included investigations into ‘single nucleotide polymorphisms (SNPs)’ or microsatellites of cytokines, cytokine receptor genes, or genes associating with innate immunity. These polymorphisms give rise to functional differences in the production of e.g. cytokines, or altered function of genes which are reflected in potential up‐ or down‐ regulating of the ‘cytokine storm’ of GvHD. This review summarises some of the studies and relates the results to their potential for improving HSCT outcome by predicting transplant‐related mortality and GvHD.
- 1 August 2008
- Published by Wiley in International Journal of Immunogenetics
- Vol. 35 (4-5) , 375-380
Non‐HLA genetics and predicting outcome in HSCT
Summary: Over the last 10 years, an increasing number of studies have demonstrated the role of non‐human leukocyte antigen (HLA) genes in predicting outcome in haematopoietic stem cell transplantation (HSCT). These studies have included investigations into ‘single nucleotide polymorphisms (SNPs)’ or microsatellites of cytokines, cytokine receptor genes, or genes associating with innate immunity. These polymorphisms give rise to functional differences in the production of e.g. cytokines, or altered function of genes which are reflected in potential up‐ or down‐ regulating of the ‘cytokine storm’ of GvHD. This review summarises some of the studies and relates the results to their potential for improving HSCT outcome by predicting transplant‐related mortality and GvHD.
- 1 June 2008
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 21 (2) , 149-164
Polymorphisms of cytokine and innate immunity genes and GVHD
- 1 June 2008
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 21 (2) , 149-164
Polymorphisms of cytokine and innate immunity genes and GVHD
- 1 June 2007
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 20 (2) , 189-207
Risk assessment in haematopoietic stem cell transplantation: Pre–transplant patient and donor factors: non-HLA genetics
- 1 June 2007
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 20 (2) , 189-207
Risk assessment in haematopoietic stem cell transplantation: Pre–transplant patient and donor factors: non-HLA genetics
- 1 January 2007
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 9 (29) , 1-19
Haematopoietic stem cell transplantation: can our genes predict clinical outcome?
Haematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for many patients with malignant and non-malignant haematological diseases. The success of HSCT is greatly reduced by the development of complications, which include graft-versus-host disease (GVHD), relapse and infection. Human leukocyte antigen (HLA) matching of patients and donors is essential, but does not completely prevent these complications; non-HLA genes may also have an impact upon transplant outcome. Polymorphisms within genes that are associated with an individual's capability to mount an immune response to alloantigen and infectious pathogens and/or response to drugs (pharmacogenomics) are all currently being studied for their association with HSCT outcome. This review summarises the potential role of non-HLA polymorphisms in predicting HSCT outcome, from studies on retrospective transplant cohorts of HLA-identical siblings and matched unrelated donors. The clinical relevance and interpretation of non-HLA genetics, and how these could be used alongside clinical risk factors in HSCT, are also discussed.
- 1 January 2007
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 9 (29) , 1-19
Haematopoietic stem cell transplantation: can our genes predict clinical outcome?
Haematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for many patients with malignant and non-malignant haematological diseases. The success of HSCT is greatly reduced by the development of complications, which include graft-versus-host disease (GVHD), relapse and infection. Human leukocyte antigen (HLA) matching of patients and donors is essential, but does not completely prevent these complications; non-HLA genes may also have an impact upon transplant outcome. Polymorphisms within genes that are associated with an individual's capability to mount an immune response to alloantigen and infectious pathogens and/or response to drugs (pharmacogenomics) are all currently being studied for their association with HSCT outcome. This review summarises the potential role of non-HLA polymorphisms in predicting HSCT outcome, from studies on retrospective transplant cohorts of HLA-identical siblings and matched unrelated donors. The clinical relevance and interpretation of non-HLA genetics, and how these could be used alongside clinical risk factors in HSCT, are also discussed.
- 1 April 2006
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 12, S19
NOD2/CARD15 Mutations Associate With Transplant-related Mortality and GvHD in HLA-Identical Sibling Transplants
- 1 April 2006
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 12, S19
NOD2/CARD15 Mutations Associate With Transplant-related Mortality and GvHD in HLA-Identical Sibling Transplants